CN108853039A - 一种克拉霉素分散片及其生产工艺 - Google Patents
一种克拉霉素分散片及其生产工艺 Download PDFInfo
- Publication number
- CN108853039A CN108853039A CN201810892116.9A CN201810892116A CN108853039A CN 108853039 A CN108853039 A CN 108853039A CN 201810892116 A CN201810892116 A CN 201810892116A CN 108853039 A CN108853039 A CN 108853039A
- Authority
- CN
- China
- Prior art keywords
- clarithromycin
- parts
- added
- dry
- tween
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002626 clarithromycin Drugs 0.000 title claims abstract description 62
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 title claims abstract description 62
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 238000005516 engineering process Methods 0.000 title claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 70
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 60
- 235000019441 ethanol Nutrition 0.000 claims abstract description 34
- 229920002472 Starch Polymers 0.000 claims abstract description 33
- 239000008107 starch Substances 0.000 claims abstract description 33
- 235000019698 starch Nutrition 0.000 claims abstract description 33
- 239000011734 sodium Substances 0.000 claims abstract description 31
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 31
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 30
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 28
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 28
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 28
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 28
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 28
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 28
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 44
- 238000002156 mixing Methods 0.000 claims description 38
- 239000011122 softwood Substances 0.000 claims description 33
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 27
- 229920000053 polysorbate 80 Polymers 0.000 claims description 27
- 235000020985 whole grains Nutrition 0.000 claims description 25
- 238000001035 drying Methods 0.000 claims description 15
- 238000005469 granulation Methods 0.000 claims description 15
- 230000003179 granulation Effects 0.000 claims description 15
- 239000004677 Nylon Substances 0.000 claims description 14
- 229920001778 nylon Polymers 0.000 claims description 14
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011812 mixed powder Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810892116.9A CN108853039B (zh) | 2018-08-07 | 2018-08-07 | 一种克拉霉素分散片及其生产工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810892116.9A CN108853039B (zh) | 2018-08-07 | 2018-08-07 | 一种克拉霉素分散片及其生产工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108853039A true CN108853039A (zh) | 2018-11-23 |
CN108853039B CN108853039B (zh) | 2021-03-09 |
Family
ID=64318374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810892116.9A Active CN108853039B (zh) | 2018-08-07 | 2018-08-07 | 一种克拉霉素分散片及其生产工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108853039B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020061333A1 (en) * | 1999-03-30 | 2002-05-23 | Noel Zakarian | Dispersible macrolide compounds and method for production thereof |
WO2004006888A2 (en) * | 2002-07-17 | 2004-01-22 | Lek Farmacevtska Druzba D.D. | Stabilization of the profile of release of active substances from a formulation |
WO2004032904A1 (en) * | 2002-10-08 | 2004-04-22 | Krka, Tovarna Zdravil, D.D. | Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate |
CN1823804A (zh) * | 2005-12-30 | 2006-08-30 | 刘展欣 | 一种克拉霉素速释微丸及其制备方法 |
CN103153304A (zh) * | 2010-05-26 | 2013-06-12 | 欧弗有限公司 | 用于治疗幽门螺旋杆菌感染的组合物 |
-
2018
- 2018-08-07 CN CN201810892116.9A patent/CN108853039B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020061333A1 (en) * | 1999-03-30 | 2002-05-23 | Noel Zakarian | Dispersible macrolide compounds and method for production thereof |
WO2004006888A2 (en) * | 2002-07-17 | 2004-01-22 | Lek Farmacevtska Druzba D.D. | Stabilization of the profile of release of active substances from a formulation |
WO2004032904A1 (en) * | 2002-10-08 | 2004-04-22 | Krka, Tovarna Zdravil, D.D. | Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate |
CN1823804A (zh) * | 2005-12-30 | 2006-08-30 | 刘展欣 | 一种克拉霉素速释微丸及其制备方法 |
CN103153304A (zh) * | 2010-05-26 | 2013-06-12 | 欧弗有限公司 | 用于治疗幽门螺旋杆菌感染的组合物 |
Non-Patent Citations (2)
Title |
---|
NOZAWA,等: "Effect of surfactants or a water soluble polymer on the crystal transition of clarithromycin during a wet granulation process", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 * |
王萍,等: "克拉霉素分散片的制备及处方工艺优化", 《海峡药学》 * |
Also Published As
Publication number | Publication date |
---|---|
CN108853039B (zh) | 2021-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100632339B1 (ko) | 아지트로마이신의 직접적으로 압축가능한 제제 | |
CN103459430B (zh) | 生产具有高堆积密度和良好流动性的纤维素衍生物的方法 | |
CN103083278B (zh) | 一种罗红霉素胶囊及其制备方法 | |
US20030190365A1 (en) | Methods for wet granulating azithromycin | |
CN109875972A (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
CN108078944A (zh) | 含有替格瑞洛的固体组合物及其制备方法 | |
CN102895203A (zh) | 一种阿奇霉素分散片的制备方法 | |
CN107320456A (zh) | N-乙酰-d-氨基葡萄糖胶囊制剂及其制备方法 | |
CN108853039A (zh) | 一种克拉霉素分散片及其生产工艺 | |
CN104739792B (zh) | 一种罗红霉素分散片制备方法 | |
CN107281155B (zh) | 一种阿奇霉素片及其制备方法 | |
CN110123770A (zh) | 一种阿哌沙班药物组合物及其制备方法 | |
CN103181905B (zh) | 一种制备盐酸普拉克索片剂的工艺 | |
CN107823173A (zh) | 一种乙酰吉他霉素胶囊及其制备方法 | |
KR101829646B1 (ko) | 투여형으로부터의 활성 성분의 방출을 제어하는 방법 | |
CN103610674B (zh) | 一种含微粉化的普拉格雷的固体制剂 | |
CN106822155A (zh) | 依非韦伦、拉米夫定及富马酸替诺福韦酯三联复方片中片及其制备方法 | |
CN113679685A (zh) | 环酯红霉素片剂的制备方法 | |
CN113768889B (zh) | 一种含西洛他唑的药物组合物及其制备方法 | |
CN110025585A (zh) | 一种阿奇霉素分散片的制备方法 | |
CN102423306A (zh) | 一种阿奇霉素肠溶胶囊 | |
CN113559073A (zh) | 阿奇霉素片剂及其制备方法 | |
CN105853389A (zh) | 磺胺嘧啶淀粉胶囊及其制备方法 | |
CN103505459B (zh) | 利奈唑胺药物组合物 | |
CN109925293A (zh) | 依普利酮口服固体制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: No.47 Zhongxing Street, Lincheng Economic Development Zone, Xingtai City, Hebei Province 054300 Patentee after: HEBEI JUNLIN PHARMACEUTICAL Co.,Ltd. Address before: 054300 North Ring East Road, Lincheng Town, Lincheng County, Xingtai City, Hebei Province Patentee before: HEBEI JUNLIN PHARMACEUTICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Clarithromycin dispersible tablet and its production process Effective date of registration: 20211116 Granted publication date: 20210309 Pledgee: Hebei Renxian Rural Commercial Bank Co.,Ltd. Pledgor: HEBEI JUNLIN PHARMACEUTICAL CO.,LTD. Registration number: Y2021130000035 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221116 Granted publication date: 20210309 Pledgee: Hebei Renxian Rural Commercial Bank Co.,Ltd. Pledgor: HEBEI JUNLIN PHARMACEUTICAL CO.,LTD. Registration number: Y2021130000035 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A clarithromycin dispersible tablet and its production process Effective date of registration: 20221213 Granted publication date: 20210309 Pledgee: Hebei Renxian Rural Commercial Bank Co.,Ltd. Pledgor: HEBEI JUNLIN PHARMACEUTICAL CO.,LTD. Registration number: Y2022130000117 |